January 9, 2018 / 2:20 PM / in a month

BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab

Jan 9 (Reuters) - Beigene Ltd:

* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB

* BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE

* BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below